Arcutis Biotherapeutics Inc’s recently made public that its insider Matsuda Masaru unloaded Company’s shares for reported $0.11 million on Feb 03 ’25. In the deal valued at $12.70 per share,8,338 shares were sold. As a result of this transaction, Matsuda Masaru now holds 178,692 shares worth roughly $2.34 million.
Then, Watanabe Todd Franklin sold 19,301 shares, generating $245,123 in total proceeds. Upon selling the shares at $12.70, the insider now owns 804,129 shares.
Before that, Welgus Howard G. sold 10,000 shares. Arcutis Biotherapeutics Inc shares valued at $127,100 were divested by the Director at a price of $12.71 per share. As a result of the transaction, Welgus Howard G. now holds 141,944 shares, worth roughly $1.86 million.
H.C. Wainwright initiated its Arcutis Biotherapeutics Inc [ARQT] rating to a Buy in a research note published on December 30, 2024; the price target was $19. A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in late August with a ‘”a Buy”‘ rating. Mizuho also remained covering ARQT and has increased its forecast on January 03, 2024 with a “Buy” recommendation from previously “Neutral” rating. Mizuho revised its rating on October 26, 2023. It rated ARQT as “a Neutral” which previously was an “a Buy”.
Price Performance Review of ARQT
On Tuesday, Arcutis Biotherapeutics Inc [NASDAQ:ARQT] saw its stock jump 3.23% to $13.10. Over the last five days, the stock has lost -5.96%. Arcutis Biotherapeutics Inc shares have fallen nearly -5.96% since the year began. Nevertheless, the stocks have risen 97.29% over the past one year. While a 52-week high of $16.20 was reached on 01/07/25, a 52-week low of $5.38 was recorded on 02/04/25. SMA at 50 days reached $13.32, while 200 days put it at $10.33.
Levels Of Support And Resistance For ARQT Stock
The 24-hour chart illustrates a support level at 12.41, which if violated will result in even more drops to 11.72. On the upside, there is a resistance level at 13.47. A further resistance level may holdings at 13.84. The Relative Strength Index (RSI) on the 14-day chart is 45.96, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.50, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 66.33%. Stochastics %K at 21.77% indicates the stock is a holding.
How much short interest is there in Arcutis Biotherapeutics Inc?
A steep rise in short interest was recorded in Arcutis Biotherapeutics Inc stocks on 2025-01-15, dropping by -2.9 million shares to a total of 20.22 million shares. Yahoo Finance data shows the prior-month short interest on 2024-12-13 was 23.11 million shares. There was a decline of -14.32%, which implies that there is a negative sentiment for the stock.
